Qubigen’s recent study on tailored federated AI for blood-brain-barrier permeability prediction has now been featured by Diagnostics World News in an article exploring why specialized AI systems are outperforming generic foundation models in life sciences.
diagnosticsworldnews.com/new…
🤖 Made with AI
Qubigen is pleased to report on a research collaboration with Dr. Srinivas Viswanathan and his team at Dana-Farber Cancer Institute. The project focuses on the discovery of novel small-molecule candidates for a rare and aggressive type of kidney cancer.
qubigen.com/post/qubigen-col…
Qubigen is excited to announce our participation in the upcoming BIO International Convention 2026 in San Diego, taking place from June 22-26, 2026.
qubigen.com/post/qubigen-to-…
Matthew Oristano, Strategic Advisor and Investor in Qubigen, will attend the Bio-IT World Conference & Expo 2026 in Boston, taking place May 19–21, 2026 to forge institutional partnerships across the AI-in-Pharma ecosystem.
qubigen.com/post/qubigen-to-…
Qubigen and University of Melbourne Secure $496,348 Federal AEA Grant to Advance AI-Driven Drug Design
qubigen.com/post/qubigen-and…
Qubigen retweeted
In just over twelve months, Qubigen has evolved from an innovative idea into a validated, capital-efficient drug design platform, demonstrating that secure, Federated AI can deliver real scientific progress, commercial traction, and scalable value.
qubigen.com/post/one-year-of…
Qubigen retweeted
Qubigen to Attend JPM Week 2026 in San Francisco, Engaging Investors & Exploring Strategic Partnerships
qubigen.com/post/qubigen-to-…
Qubigen retweeted
Qubigen is pleased to announce the signing of an agreement with QIMR Berghofer, establishing a framework to accelerate the development of novel drug candidates targeting tumorigenesis and cancer progression.
qubigen.com/post/qimr-bergho…
Qubigen retweeted
At Qubigen, we do something fundamentally different: we build AI Engines for drug design using our secure Federated AI Drug Design platform (FedAIDD). Our clients generate truly novel compounds, without their data ever leaving its server.
qubigen.com/post/federated-a…
Qubigen retweeted
Qubigen's CEO, Dr Jonathan Hall, and Chief Information Officer, A/Prof Dr Jun Zeng, will be presenting at the Walter and Eliza Hall Institute of Medical Research (WEHI) Divisional Seminar Program
10:45 AM, Thursday, 20 November 2025
qubigen.com/post/qubigen-to-…
Qubigen retweeted
Qubigen CEO Dr. Jonathan Hall to Speak at SBEI25 on Federated AI for Global Health & Drug Design
qubigen.com/post/qubigen-ceo…
Qubigen retweeted
We’re excited to introduce the next group of Xtalks Featured Community Members, celebrating the people advancing life sciences across pharma, biotech, medtech, healthcare and beyond. Our newest members include:
· Christopher Missling, PhD, President & CEO, Anavex Life Sciences
· Jonathan Hall, PhD, Founder & CEO, Qubigen
· Mark Franklin, Manager, Curation, DrugBank
· Petra Elischer, Head of Quality and Regulatory Affairs, Hart Biologicals Limited
· Rebecca Starkie, Consultant, Civia Health
Meet them all at buff.ly/LSA0I1d and learn how to apply or nominate a colleague at buff.ly/LdsbLY7.
#LifeSciences #Biotech #Pharma #MedTech #ClinicalResearch #XtalksCommunity #Leadership
Qubigen retweeted
Qubigen is pleased to announce that Matthew Oristano, Strategic Advisor and Investor in Qubigen, will be attending Discovery on Target (DOT) 2025 in Boston, taking place on September 22nd–25th, 2025.
qubigen.com/post/qubigen-to-…
Qubigen retweeted
Qubigen Signs Agreement with SyzOnc to Apply AI-Driven Drug Development to Promising Oncology Targets
qubigen.com/post/qubigen-sig…
Qubigen retweeted
Qubigen Signs Data Access Agreement with Flinders University, enabling Qubigen to apply its Federated AI platform and proprietary quantum chemistry-based drug design technologies to research programs in partnership with Flinders University. qubigen.com/post/qubigen-sig…










